Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?

Basit Öğe Kaydı
dc.contributor.authorEker, Salih Saygın
dc.contributor.authorYavaşçı, Ebru Öztepe
dc.contributor.authorCangür, Şengül
dc.contributor.authorKırlı, Selçuk
dc.contributor.authorSarandöl, Emre
dc.date.accessioned2020-04-30T22:40:27Z
dc.date.available2020-04-30T22:40:27Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000344995200005en_US
dc.descriptionPubMed: 25241757en_US
dc.description.abstractObjective: The aim of the current study is to determine whether serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-2 (IL-2) can be biological indicators for the diagnosis of schizophrenia in patients with depressive symptoms. Method: Forty-seven patients (11 patients diagnosed with schizophrenia, 16 patients diagnosed with schizophrenia and comorbid depression and 20 patients diagnosed with major depressive disorder) and 20 healthy subjects were enrolled. The Positive and Negative Symptoms Scale, the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale were used for assessment. The serum BDNF and IL-2 levels of all the subjects were studied. Results: Decreased levels of serum BDNF and increased levels of serum IL-2 were found in the patients diagnosed with either schizophrenia, schizophrenia with depression, or major depressive disorder (p = 0.049, p = 0.010; p = 0.001 and p = 0.044; p = 0.027, p = 0.003; respectively) compared with control group. There were no significant differences between the patient groups in their serum BDNF and IL-2 levels. Conclusions: The present study suggests that neurotrophic factors and immune system changes are involved in the pathogenesis of schizophrenia with or without depressive symptomatology. However, the data do not clarify whether depressive symptoms in schizophrenia occur as a dimension of schizophrenia or as symptoms of major depression that is comorbid with schizophrenia.en_US
dc.identifier.doi10.1017/neu.2014.13en_US
dc.identifier.endpage297en_US
dc.identifier.issn1601-5215
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage291en_US
dc.identifier.urihttps://doi.org/10.1017/neu.2014.13
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2985
dc.identifier.volume26en_US
dc.identifier.wosWOS:000344995200005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCambridge Univ Pressen_US
dc.relation.ispartofActa Neuropsychiatricaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcomorbidityen_US
dc.subjectdepressionen_US
dc.subjectpsychoneuroimmunologyen_US
dc.subjectschizophreniaen_US
dc.titleCan BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
2985.pdf
Boyut:
105.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu